AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29211618 — intervention group
Group type: COMPARATOR
Intervention: Combined positive lymph node status and LOH 1p or 16q
Number of subjects: 535
Study 29211618 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed nephrectomy (histology results)
Number of subjects: 535
Study 29211620 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 4252
Study 29211620 — intervention group
Group type: COMPARATOR
Intervention: quadrivalent HPV vaccine (qHPV)
Number of subjects: 4252
Study 29211678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with AAV vector (5×10 dose)
Number of subjects: 10
Study 29211678 — intervention group
Group type: COMPARATOR
Intervention: Before vector administration
Number of subjects: 10
Study 29211678 — intervention group
Group type: EXPERIMENTAL
Intervention: After vector administration
Number of subjects: 10
Study 29211870 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (fixed-dose, cumulative dose 47 to 98 mg/kg for 1.3 to 4 years)
Number of subjects: 3
Study 29211870 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (fixed-dose)
Number of subjects: 3
Study 29212126 — intervention group
Group type: EXPERIMENTAL
Intervention: extended-duration betrixaban (35–42 days)
Number of subjects: 7513
Study 29212126 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin (10 ± 4 days)
Number of subjects: 7513
Study 29212126 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer ≥ 2×ULN
Number of subjects: 7513
Study 29212126 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer at baseline
Number of subjects: 7513
Study 29212518 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL-C levels
Number of subjects: 775
Study 29212518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C levels
Number of subjects: 775
Study 29212518 — intervention group
Group type: COMPARATOR
Intervention: HDL-C category or continuous HDL-C levels
Number of subjects: 775
Study 29212544 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin daily
Number of subjects: 61
Study 29212544 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 61
Study 29212734 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant GTX (gemcitabine 750 mg/m², docetaxel, capecitabine)
Number of subjects: 40
Study 29213110 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO for 8 minutes
Number of subjects: 0
Study 29213213 — intervention group
Group type: EXPERIMENTAL
Intervention: Course in group leadership
Number of subjects: 56
Study 29213243 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) efficacy on CHF patients
Number of subjects: 110
Study 29213269 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-TRAP and EPI vaccines
Number of subjects: 65
Study 29213269 — intervention group
Group type: COMPARATOR
Intervention: EPI vaccines only
Number of subjects: 65
Study 29213281 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (mean dose 1100 mg, with some patients receiving above 1000 mg)
Number of subjects: 282
Study 29213281 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Number of subjects: 282
Study 29214012 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of perennial AIT using PURETHAL Mites
Number of subjects: 58
Study 29214012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 29214034 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (~10 mg/kg/month)
Number of subjects: 144
Study 29214034 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 144
Study 29214034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 29214042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle enhanced Parents as Teachers curriculum (PATE)
Number of subjects: 0
Study 29214042 — intervention group
Group type: COMPARATOR
Intervention: Parents as Teachers curriculum (PAT)
Number of subjects: 0
Study 29214306 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2348
Study 29214306 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2348
Study 29214306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RYGB and LAGB
Number of subjects: 2348
Study 29214505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-based cryogenic device (EndWarts Freeze)
Number of subjects: 0
Study 29214505 — intervention group
Group type: COMPARATOR
Intervention: Dimethylether propane-based product (Wartner)
Number of subjects: 0
Study 29214922 — intervention group
Group type: EXPERIMENTAL
Intervention: HAES®-based intervention (exercise program, nutrition counseling sessions, philosophical workshops)
Number of subjects: 60
Study 29214922 — intervention group
Group type: COMPARATOR
Intervention: Traditional HAES®-based group format (bimonthly lectures)
Number of subjects: 60
Study 29216318 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-by-day approach
Number of subjects: 676
Study 29216318 — intervention group
Group type: COMPARATOR
Intervention: Week-by-week approach
Number of subjects: 676
Study 29216353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy in transwomen
Number of subjects: 69
Study 29216353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy in transmen
Number of subjects: 69
Study 29216356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined isolation of exosomal RNA (exoRNA) and cell-free DNA (cfDNA) (exoNA)
Number of subjects: 84
Study 29216356 — intervention group
Group type: COMPARATOR
Intervention: Circulating tumor DNA (ctDNA) by BEAMing
Number of subjects: 84
Study 29216356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined isolation of exosomal RNA (exoRNA) and cell-free DNA (cfDNA) (exoNA) in M0/M1a subgroup (n=21)
Number of subjects: 84
Study 29216358 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 6583
Study 29216358 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCG)
Number of subjects: 6583
Study 29216400 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg bd
Number of subjects: 53
Study 29216439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 80
Study 29216439 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 80
Study 29216838 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine mobilisation and targeted hospital interventions for patients identified with reduced physical performance.
Number of subjects: 117
Study 29216838 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified prediction model based on 4 variables: use of a walking aid before hospitalisation, a 30s-CST score ≤ 5, age > 85, and female gender.
Number of subjects: 117
Study 29216886 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of PCIT into existing practices
Number of subjects: 12
Study 29216886 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality monitoring
Number of subjects: 12
Study 29216886 — intervention group
Group type: EXPERIMENTAL
Intervention: Financing
Number of subjects: 12
Study 29216999 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bioresorbable scaffolds (BRS)
Number of subjects: 657
Study 29216999 — intervention group
Group type: COMPARATOR
Intervention: Optimal implantation technique
Number of subjects: 657
Study 29216999 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference vessel diameter (RVD) and BRS sizing
Number of subjects: 657
Study 29216999 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete BRS deployment
Number of subjects: 657
Study 29216999 — intervention group
Group type: EXPERIMENTAL
Intervention: Large vessel size and BRS undersizing
Number of subjects: 657
Study 29217099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) scores during pregnancy
Number of subjects: 1078
Study 29217288 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed disease progression, unacceptable toxicity, or other criterion for withdrawal.
Number of subjects: 249
Study 29217502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Intervention (coaching software on mobile phone)
Number of subjects: 163
Study 29217502 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 163
Study 29217776 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan 200 mg/m
Number of subjects: 0
Study 29217778 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutional mutations (p.H880Q, p.R986H, p.R986C, p.V1512M) identified through genomic studies
Number of subjects: 7
Study 29218759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) using EQ-5D-5L
Number of subjects: 381
Study 29218759 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory v2 Short Form
Number of subjects: 381
Study 29218759 — intervention group
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire
Number of subjects: 381
Study 29218759 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36v2 health survey
Number of subjects: 381
Study 29218759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophilia Activities List
Number of subjects: 381
Study 29218759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophilia Joint Health Score v2.1 (HJHS)
Number of subjects: 381
Study 29219612 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab treatment
Number of subjects: 88
Study 29220505 — intervention group
Group type: EXPERIMENTAL
Intervention: ab+/ins- (antibody positive/insulin negative)
Number of subjects: 41
Study 29220505 — intervention group
Group type: EXPERIMENTAL
Intervention: ab+/ins+ (antibody positive/insulin positive)
Number of subjects: 41
Study 29220505 — intervention group
Group type: EXPERIMENTAL
Intervention: ab-/ins- (antibody negative/insulin negative)
Number of subjects: 41
Study 29220505 — intervention group
Group type: COMPARATOR
Intervention: Controls (glucose-tolerant humans)
Number of subjects: 41
Study 29220868 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic cohort (DM)
Number of subjects: 4839770
Study 29220868 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic cohort (non-DM)
Number of subjects: 4839770
Study 29221433 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 24
Study 29221433 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 29221483 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 34
Study 29221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap-smears performed by GPs
Number of subjects: 347
Study 29221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Male GPs performing pap-smears
Number of subjects: 347
Study 29221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Female GPs performing pap-smears
Number of subjects: 347
Study 29221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening rates in target population when GPs performed smears
Number of subjects: 347
Study 29221494 — intervention group
Group type: COMPARATOR
Intervention: Screening rates in target population when GPs did not perform smears
Number of subjects: 347
Study 29221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of claim code by GPs
Number of subjects: 347
Study 29221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of number of patients and EDI with pap-smears
Number of subjects: 347
Study 29221777 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 246
Study 29221777 — intervention group
Group type: COMPARATOR
Intervention: Nonthrombolysis
Number of subjects: 246
Study 29222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Facebook content (1 to 2 status updates per day)
Number of subjects: 21
Study 29222077 — intervention group
Group type: COMPARATOR
Intervention: Static Facebook content (96 statuses viewed on the first day)
Number of subjects: 21
Study 29222080 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item self-report WHODAS 2.0 administered online
Number of subjects: 160
Study 29222121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 87
Study 29222199 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks
Number of subjects: 7
Study 29222199 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 7
Study 29222649 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (two 220 mg capsules of zinc sulfate per day for 3 months)
Number of subjects: 60
Study 29223443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d) for 18 months
Number of subjects: 101
Study 29223478 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 300 mg twice-daily (N = 3) then 400 mg twice-daily (N = 15) days 1-28
Number of subjects: 16
Study 29223912 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine dose at delivery
Number of subjects: 41
Study 29223912 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine dose
Number of subjects: 41
Study 29223912 — intervention group
Group type: COMPARATOR
Intervention: NNNS domain scores
Number of subjects: 41
Study 29224196 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cervical angle (PCA) > 99.5°
Number of subjects: 70
Study 29224196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length < 34 mm
Number of subjects: 70
Study 29224196 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score > 5
Number of subjects: 70
Study 29224239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise vascular occlusion technique
Number of subjects: 80
Study 29224367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (starting dose of 15 or 20 mg BID, final titrated dose of ≥10 mg BID)
Number of subjects: 81
Study 29224367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (higher doses of 20 or 25 mg BID)
Number of subjects: 81
Study 29224367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 81
Study 29224506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AAV5-hFVIII-SQ
Number of subjects: 9
Study 29224973 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pulmonary embolism with percentage of vascular obstruction 0.1%-4.9%
Number of subjects: 239
Study 29224973 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pulmonary embolism with percentage of vascular obstruction 5.0%-9.9%
Number of subjects: 239
Study 29224973 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pulmonary embolism with percentage of vascular obstruction greater than or equal to 10%
Number of subjects: 239
Study 29224973 — intervention group
Group type: COMPARATOR
Intervention: No residual pulmonary embolism on baseline ventilation-perfusion scan
Number of subjects: 239
Study 29225195 — intervention group
Group type: EXPERIMENTAL
Intervention: First 1000Days program
Number of subjects: 3
Study 29225893 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Jejunal Diversion (PJD)
Number of subjects: 15
Study 29225899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group parents
Number of subjects: 0
Study 29225899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29225903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor as loading P2Y inhibitor
Number of subjects: 0
Study 29225903 — intervention group
Group type: COMPARATOR
Intervention: Heparin with optional glycoprotein IIb/IIIa inhibitor treatment
Number of subjects: 0
Study 29225901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 14
Study 29225901 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 14
Study 29226174 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 218
Study 29226174 — intervention group
Group type: COMPARATOR
Intervention: Matched non-HIV-infected subjects
Number of subjects: 218
Study 29226268 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 1
Study 29226268 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (one drop daily at bedtime for seven days)
Number of subjects: 1
Study 29226268 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol, atropine, and prednisolone
Number of subjects: 1
Study 29226764 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019 cells (CD19-directed CAR T cells)
Number of subjects: 28
Study 29226797 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) CAR T-cell therapy
Number of subjects: 111
Study 29228942 — intervention group
Group type: COMPARATOR
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in healthy controls
Number of subjects: 153
Study 29228942 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in patients with sarcoidosis
Number of subjects: 153
Study 29228942 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in patients with bronchial asthma
Number of subjects: 153
Study 29228942 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in patients with COPD
Number of subjects: 153
Study 29228942 — intervention group
Group type: EXPERIMENTAL
Intervention: Test time reduction in COPD
Number of subjects: 153
Study 29228942 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-test repeatability of LCI
Number of subjects: 153
Study 29228942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean absolute changes in LCI
Number of subjects: 153
Study 29228998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Perception Screening Questionnaire-9 (NPSQ9)
Number of subjects: 2369
Study 29228998 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutritional advice based on NPSQ9 scores
Number of subjects: 2369
Study 29229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual assessments of endothelial function by flow-mediated dilatation (FMD)
Number of subjects: 76
Study 29229089 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walking distance
Number of subjects: 76
Study 29229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive airway obstruction
Number of subjects: 76
Study 29229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 76
Study 29229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual decline in FEV1
Number of subjects: 76
Study 29229100 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 67
Study 29229365 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone-derived mesenchymal stem cells (H-MSV) seeded on a cross-linked serum scaffold (BioMax)
Number of subjects: 9
Study 29229365 — intervention group
Group type: COMPARATOR
Intervention: Contralateral control area of spongy alveolar bone without treatment
Number of subjects: 9
Study 29229591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention delivered entirely through an online social network
Number of subjects: 0
Study 29229591 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinic-based lifestyle intervention
Number of subjects: 0
Study 29229594 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) and nivolumab (Nivo) combination treatment
Number of subjects: 62
Study 29230307 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO PST programme delivered by family volunteers
Number of subjects: 540
Study 29230323 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA treatment
Number of subjects: 85
Study 29230323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 29230539 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) at a dose of 0.4 mg/kg
Number of subjects: 41
Study 29230539 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 41
Study 29232153 — intervention group
Group type: COMPARATOR
Intervention: 0 ppb ozone
Number of subjects: 87
Study 29232153 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 ppb ozone
Number of subjects: 87
Study 29232153 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 ppb ozone
Number of subjects: 87
Study 29232322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 119
Study 29232322 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 119
Study 29232322 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 119
Study 29233022 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter implantation (TAVI)
Number of subjects: 36
Study 29233022 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 36
Study 29233119 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD-AD (active state of disease)
Number of subjects: 47
Study 29233119 — intervention group
Group type: COMPARATOR
Intervention: IBD-RE (remission-group)
Number of subjects: 47
Study 29233119 — intervention group
Group type: COMPARATOR
Intervention: HC (healthy controls)
Number of subjects: 47
Study 29233163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous bone marrow mesenchymal stem cells (BM-MSCs)
Number of subjects: 13
Study 29233751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from children with PANDAS
Number of subjects: 5
Study 29233751 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 5
Study 29233751 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with intravenous immunoglobulin
Number of subjects: 5
Study 29233792 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation (2 × 600mg, twice daily, for 30 days)
Number of subjects: 36
Study 29233792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29233821 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib (IPI-145)
Number of subjects: 35
Study 29234302 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based virtual reality training
Number of subjects: 12